Cited by 874HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 73 of the 83 references it cites were found in a registry or an index.

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Open access

Agus, David B, Akita, Robert W, Fox, William D, Lewis, Gail D, Higgins, Brian, Pisacane, Paul I, Lofgren, Julie A, Tindell, Charles, Evans, Douglas P, Maiese, Krista, Scher, Howard I, Sliwkowski, Mark X·2002·Cancer Cell

DOI 10.1016/s1535-6108(02)00097-1

Open this paper in CoChat — free account Open PDF

Abstract

ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in both low- and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00097-1

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citation
Real time quantitative PCR.Preprint
Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
A novel method for real time quantitative RT-PCR.Preprint
Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617
The EGF receptor family as targets for cancer therapy
Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Show all 83 references

Research works printed but not linked: 6

Agus, 1999, Prostate cancer cell cycle regulators, J. Natl. Cancer Inst., 91, 1869, 10.1093/jnci/91.21.1869 · DOI
Lewis, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin, Cancer Res., 56, 1457
Nagabhushan, 1996, CWR22, Cancer Res., 56, 3042
Pinkas-Kramarski, 1996, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO J., 15, 2452, 10.1002/j.1460-2075.1996.tb00603.x · DOI
Tzahar, 1998, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas, Biochim. Biophys. Acta, 1377, M25
Wainstein, 1994, CWR22, Cancer Res., 54, 6049

Sorted by citations

Items 701–800 of 874

Development of antibody-based therapeutics for oncology indications
Li, Y., & Zhu, Z. (2006) · Drug Development Research · doi:10.1002/ddr.20146 · Cited by 4
Hormone-Refractory Prostate Cancer
Joaquim Bellmunt, B. (2008) · Springer eBooks · doi:10.1007/978-3-540-47648-1_2813 · Cited by 4
The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options
von Arx, C., Calderaio, C., Calabrese, A., Marciano, B., Martinelli, C., Lauro, V. D., Cerillo, I., Cianniello, D., & Laurentiis, M. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1447508 · Cited by 3
RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody
Hu, S., Dai, H., Zhang, T., Fu, W., Berezov, S. D., Chen, C., Jorissen, D., Takeda, H., & Bethune, A. N. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.053 · Cited by 3
Retracted
Pharmacological properties and clinical development overview of pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) (PHESGO® combination for subcutaneous injection MA, IN)
Sakaeda, M., Kotani, N., Yoneya, T., Zheng, Y., & Habara, Y. (2024) · Folia Pharmacologica Japonica · doi:10.1254/fpj.24022 · Cited by 4
Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody–drug conjugates
Bai, X., Xu, L., Wang, Z., Zhuang, X., Ning, J., Sun, Y., Wang, H., Guo, Y., Xu, Y., Guo, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413686122 · Cited by 5
A Specific Nonenal-Binding Peptide, P4 Screened by Phage Display can Remove Trans-2-Nonenal
Lee, S., Lee, J., Hwang, A. R., Kim, Y., & Min, J. (2020) · Molecular Biotechnology · doi:10.1007/s12033-020-00238-y · Cited by 3
Signal Transduction by the Ras–MAP Kinase Pathway in Prostate Cancer Progression
Gioeli, D. G., Kraus, S. R., & Weber, M. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-079-3_11 · Cited by 3
ErbB tyrosine kinase receptor inhibitors in breast cancer treatment
Albanell, J., Mateo, M. M., & Gascón, P. (2004) · Revista de Oncología · doi:10.1007/bf02710297 · Cited by 3
Breast Cancer Genomics
Kumar, B. (2014) · Springer eBooks · doi:10.1007/978-81-322-0843-3_4 · Cited by 3
Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Cozzi, P. J., Kearsley, J. H., & Li, Y. (2008) · Current Cancer Therapy Reviews · doi:10.2174/157339408786413371 · Cited by 3
HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies
Tsang, R. Y., & Finn, R. S. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.04.004 · Cited by 3
A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity
Huang, Y., Burns, D. J., Rich, B. E., MacNeil, I. A., Dandapat, A., Soltani, S. M., Myhre, S., Sullivan, B. F., Furcht, L. T., Lange, C. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12480 · Cited by 3
Resistance to HER2-Targeted Therapy
Theile, D., Lenz, G., Momand, J. A., & Kane, S. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_2 · Cited by 3
Synergistic antitumor effect of the anti‑ErbB2 antibodies trastuzumab and H2‑18 on trastuzumab‑resistant gastric cancer cells
Wang, C., Wang, L., Liang, B., Zhou, B., Sun, Y., Meng, Y., Dong, J., Chen, L., & Li, B. (2021) · Oncology Letters · doi:10.3892/ol.2021.12661 · Cited by 3
Impact of Chemotherapeutic Drugs Towards Oxidative Stress and Associated Multi-organ Physiological Responses
Chakraborti, S., Stewart, A., & Maity, B. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_248 · Cited by 3
Neuregulin 1 and Schizophrenia
Chen, Y.-J. J., Role, L. W., & Talmage, D. A. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_6 · Cited by 3
Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways
Reid, A. H. M., Baird, R. D., & Workman, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_17 · Cited by 3
Human epidermal growth factor receptor 2-targeted therapies in breast cancer
Nahta, R. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789497 · Cited by 3
Anticancer Target Combinations: Network- Informed Signaling-Based Approach to DiscoveryPreprint
Yavuz, B. R., Jang, H., & Nussinov, R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.11.617918 · Cited by 3
Predictors of pathological complete response to neoadjuvant treatment in invasive breast cancer with different human epidermal growth factor receptor 2 (HER2) subcategories
Sun, B., Li, Y., Wang, J., Lu, H., & Li, J. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-24-397 · Cited by 2
Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells
Liu, X., Guo, L., Wang, Y., Meng, X. M., Shao, Y., Fan, X., Wang, C., Zhu, W., Cao, J., & Sun, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711448 · Cited by 2
Molecular Targeted Anticancer Drugs
Kim, K., Roh, J. K., Wee, H., & Kim, C. (2016) · Springer eBooks · doi:10.1007/978-94-024-0844-7_9 · Cited by 2
HER Receptor, Current, and Emerging Therapeutic Targets
Tan, M., Yeap, J. W., & Matawali, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_258-1 · Cited by 3
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
Osako, T., Nishimura, R., Nishiyama, Y., & Fujisue, M. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.640 · Cited by 2
Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond
Zardavas, D., Pugliano, L., Ades, F., Božović‐Spasojević, I., Capelán, M., & de Azambuja, E. (2012) · Breast Cancer Management · doi:10.2217/bmt.12.35 · Cited by 2
Resistance to HER2-Targeted Therapy in HER2+ Breast Cancer
Kessler, E., & Elias, A. (2012) · Clinical Medicine Reviews in Women s Health · doi:10.4137/cmrwh.s3272 · Cited by 2
Cancer therapies targeted to the epidermal growth factor receptor and its family members
Kane, S. E. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.2.147 · Cited by 2
The EGFR/ErbB Family in Breast Cancer: From Signalling to Therapy
Köstler, W. J., & Yarden, Y. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0094-1_1 · Cited by 2
Applications of Small-Animal Molecular Imaging in Drug Development
Niu, G., & Chen, X. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0894-3_24 · Cited by 2
The ErbB2 receptor in gastric cancer: the quick-change artist
Malaguti, P., D’Aloia, M. M., & Alimandi, M. (2015) · IRIS Research product catalog (Sapienza University of Rome) · doi:10.3978/j.issn.2224-4778.2015.06.01 · Cited by 2
Novel Targeted Therapy for Advanced Gastric Cancer
Xu, H. (2015) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000154 · Cited by 2
Novel Treatments in Breast Cancer
Kingston, B., & Johnston, S. R. D. (2016) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18492 · Cited by 2
Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer
Hsu, J. L., & Hung, M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_3 · Cited by 2
Functional analysis implicating the SNP rs61552325 in ERBB2 as an effector for androgen-insensitive prostate cancer cell invasion
Xin, X., Gu, Y., Chen, Y., Huang, Y., Mo, Z., & Hu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.16807 · Cited by 2
Quantitative Determination of Intracellular Bond Cleavage
Walker, J. A., Sorkin, M. R., & Alabi, C. A. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_14 · Cited by 2
Receptor Tyrosine Kinases as Targets for Cancer Therapy Development
Gschwind, A., Fischer, O. M., & Ullrich, A. (2006) · Springer eBooks · doi:10.1007/3-540-34447-0_11 · Cited by 2
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
Zhang, N., Williams, B. R., Lü, P., An, Z., & Chin, C. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch31 · Cited by 2
HER receptor-mediated dynamic signalling in breast cancer cells
Hu, H. (2011) · ERA · Cited by 2
Neoplasms of the Breast
Rugo, H. S., Majure, M. C., Dragun, A. J., Buxton, M., & Esserman, L. J. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm109 · Cited by 2
Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy
Liu, X., Yu, W., Wang, Y., Xing, D., Huang, H., Zhu, W., & Sun, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711433 · Cited by 1
Production and Characterization of Monoclonal Antibodies Against the Dimerization Domain of Human HER2
Nadri, M., Soukhtanloo, M., Jafarian, A. H., Alamdari, M., Sisakhti, M., Kianoush, T., & Avval, F. Z. (2015) · Avicenna Journal of Medical Biochemistry · doi:10.17795/ajmb-29918 · Cited by 1
The Biology of the HER Family and Her2/neu Directed-Antibody Therapy
Litton, J. K., & Hortobágyi, G. N. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_13 · Cited by 1
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008
Tripathy, D. (2008) · Clinical Breast Cancer · doi:10.1016/s1526-8209(11)70524-9 · Cited by 1
Perspectives: Other ErbB2-Targeted Therapies
Nitz, U. A. (2010) · Breast Care · doi:10.1159/000285779 · Cited by 1
Disease models of cancer: HER2 and breast cancer
Grunt, T. W., Singer, C. F., & Solca, F. (2004) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2004.02.001 · Cited by 1
Challenges in the treatment of ErbB2 (HER2)-positive breast cancer
Jackisch, C. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)70275-1 · Cited by 1
Antibody Therapy of Cancer
Borghaei, H., Binyamin, L., Astsaturov, I. A., & Weiner, L. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_16 · Cited by 1
Targeting of HER Family Signaling Pathways in Gastric Cancer
Perkins, J. W. B. (2014) · Chemotherapy Open access · doi:10.4172/2167-7700.1000e125 · Cited by 1
Characterization of a new dual-targeting fully human antibody with potent antitumor activity against nasopharyngeal carcinoma
Xie, S., Zhu, X., Li, Y., Li, L., Yi-min, S., & Yang, N. Y. (2014) · Biological Chemistry · doi:10.1515/hsz-2014-0236 · Cited by 1
Novel Approaches to Androgen Receptor Blockade
Mellinghoff, I. K. (2006) · Translational medicine series · doi:10.3109/9781420019858.010 · Cited by 1
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
Moore, K. M., Cerqueira, V., MacLeod, K. G., Mullen, P., Hayward, R. L., Green, S. R., Harrison, D. J., Cameron, D., & Langdon, S. P. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00074 · Cited by 1
Effects of Oncogene Neuregulin 1 on Breast Cancer Cells
Li, Q., Zhu, B., Chen, J., Wang, H., Wu, Y. K., Chen, H., & He, X. (2022) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2022.345.352 · Cited by 1
Impact of Chemotherapeutic Drugs Towards Oxidative Stress and Associated Multi-organ Physiological Responses
Chakraborti, S., Stewart, A., & Maity, B. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_248-1 · Cited by 1
Understanding mechanisms of resistance to HER2-targeted therapies in HER2-positive breast cancer
Nakajima, H., & Mukohara, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00011-7 · Cited by 1
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Nelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.63 · Cited by 1
HER-2-based design of pertuzumab mimetic peptides
Keshavarz, F., Mohammad-Aghaie, D., & Khayamian, T. (2015) · Molecular Simulation · doi:10.1080/08927022.2014.985674 · Cited by 1
Anti-HER2 Therapies in the Adjuvant and Advanced Disease Settings
Munzone, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_47 · Cited by 1
Immunology and Immunotherapy of Ovarian Cancer
Wilczyński, J. R., Nowak, M., & Wilczyński, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_20 · Cited by 1
PROSTATE CANCER
Holstein, S. A., & Hohl, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50071-8 · Cited by 1
Pertuzumab (PERJETA^|^#174; Intravenous Infusion 420 mg/14 mL): pharmacological properties and clinical development overview
Myobudani, H., Ushiyama, N., Ichinose, R., & Takasuka, T. (2014) · Folia Pharmacologica Japonica · doi:10.1254/fpj.143.95 · Cited by 1
Conformational plasticity in drug design: Towards the development of inhibitors of oncogenic fusion proteins with protein tyrosine kinase activity
Gasser, M. (2005) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-005066591 · Cited by 1
Mechanisms of resistance to lapatinib in HER2 positive breast cancer
McDermott, M. S. J. (2012) · Arrow@dit (Dublin Institute of Technology) · Cited by 1
Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer
Jimeno, A., & Cortés-Funes, H. (2005) · Current Cancer Therapy Reviews · doi:10.2174/1573394052952519 · Cited by 1
HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology
Dizon, D. S., & Makhija, S. K. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.11.1363 · Cited by 1
Future options in the treatment of ErbB2 (HER2)-positive breast cancer
Fumoleau, P. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)70277-5 · Cited by 1
Novel Experimental Therapeutic Approaches for Prostate Cancer
Cavarretta, I. T. R., Čulig, Z., Klocker, H., & Eder, I. E. (2005) · EAU Update Series · doi:10.1016/j.euus.2005.09.007 · Cited by 1
Understanding the effects of therapeutic HER2 antibodies trastuzumab and pertuzumab on HER2-mediated cell signaling
Maadi, H. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-74bb-e058 · Cited by 1
Intercellular Targets of Prostate Cancer
Whang, Y. E., & George, D. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-224-3_25 · Cited by 1
Human melanoma cell lines that possess wild-type BRAF alleles but are dependent on ERBB4 and ERBB2Preprint
Dwivedi, V., Lucas, L. M., Cooke, R. H., Davis, J., Wilson, E., Scott, M., O’Daniel, K., Dion, C., Kerley, J., Zelan, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.22.609260 · Cited by 1
Monoclonal Antibody Strategies for Targeting HER2
Albanell, J., Ross, J. S., Pronk, L. C., & Gascón, P. (2007) · Humana Press eBooks · doi:10.1385/1-59259-893-5:627
Evaluation of protein and biological biomarkers in breast cancer
Rosin, G. (2015) · Figshare
The genetic and functional basis of three inherited cutaneous and gastrointestinal diseases in humans
Brooke, M. A. (2014)
Cardiac toxicity with monoclonal antibodies therapy
Mazek, H., Verma, R., & Wischmeyer, J. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.12746/swrccc.v3i11.221
Vaccination against Her2/neu - expressing cancer using chimeric virus-like particles
Andreasson, K. (2009) · Figshare
Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer
Baselga, J. M., & Cortés, J. (2007) · Springer eBooks · doi:10.1007/978-3-540-28266-2_32
Anti-cancer mechanisms of the natural plant derived compound, Withaferin A in HER-2/neu breast cancer
Barnette, A. R. (2014)
17 Expression and gene copy number alterations of her-2/neu (ERBB2) gene in prostate cancer
(2002) · Handbook of immunohistochemistry and in situ hybridization of human carcinomas · doi:10.1016/s1874-5784(02)80049-6
EGFR & HER2 trafficking and signaling dynamics : experimental and modeling studies
Hendriks, B. S. (2003)
Co-Targeting Therapeutics for Hormone Refractory Prostate Cancer
Assikis, V. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-224-3_24
Molecular imaging and sensing using plasmonic nanoparticles
Crow, M. J. (2010) · DukeSpace (Duke University)
Tiermodelle in der biomedizinischen Forschung
Britsch, S., Strehle, M., & Birchmeier, C. (2003) · Springer eBooks · doi:10.1007/978-3-662-07588-3_10
The Issue Of Compliance In Patients With Treatment Resistance Depressions = Проблема Комплаєнсу У Хворих З Терапевтично Резистентними Депресіями
Rakhman, L. V., & Маркова, М. В. (2015) · Journal of Education, Health and Sport (Kazimierz Wielki University in Bydgoszcz) · doi:10.5281/zenodo.27441
Pertuzumab et T-DM1 : de nouvelles perspectives dans le traitement du cancer du sein HER2 positif
Guiu, S., & Fumoleau, P. (2015) · ONCOLOGIE · doi:10.1007/s10269-015-2484-5
Tyrosine kinase as molecular target of anti-tumor drug.
Maru, Y. (2003) · Folia Pharmacologica Japonica · doi:10.1254/fpj.122.473
Pertuzumab – a HER-2 Dimerisation Inhibitor – for the Treatment of Breast and Other Cancers
Bianchi, G., & Gianni, L. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0094-1_5
Incorporating Agents that Target HER2 in the Neoadjuvant Setting
von Minckwitz, G., Loibl, S., Maisch, A., & Untch, M. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0054-4
Evolving Molecular-Based Targeted Therapy for Cancer: An Exciting Field
Carneiro, B. A., Hsiao, K., & Khandekar, J. D. (2005) · Comprehensive Therapy · doi:10.1385/comp:31:4:299
HER-2/NEU-TARGETED IMMUNOPREVENTION OF BREAST CANCER
Sas, S. (2007) · University Library - University of Saskatchewan (University of Saskatchewan)
Molecular Targets for Treatment of Breast Cancer
Park, W. C., Kim, L. S., Kim, T. H., Park, B., Park, H. Y., Song, B. J., Lee, J. B., Jeon, C. W., & Choi, U.-J. (2009) · Journal of Breast Cancer · doi:10.4048/jbc.2009.12.4.229
Predictive factors in esophageal carcinoma.
Dreilich, M. (2006) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Commentary Essential function for ErbB3 in breast cancer proliferation
Pérez‐Nadales, E., & Lloyd, A. C. (2004)
HER2/neu as a Prognostic Marker and Therapy Target in Prostate Cancer
Pachkoria, V., Shoshiashvili, V., Karazanashvili, G., & Gm, B. (2014)
Life After Trastuzumab: Neu Strategies For Her2-Positive Breast Cancer
Higa, G. M., & Cheng, R. M. (2013) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.810571
Will Single-Time Tumor Profiling and a “Guilt by Association” Approach Allow Us to Outsmart HER2-Positive Breast Cancer?
Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2717
UNIVERSITA' DI NAPOLI "FEDERICO II" DOTTORATO DI RICERCA BIOCHIMICA E BIOLOGIA MOLECOLARE E CELLULARE XXIII CICLO
Malara, A. E. (2011)
Development of Inhibitors of HER2 With Taxanes
Modi, S., Fornier, M. N., & Seidman, A. D. (2005) · Humana Press eBooks · doi:10.1385/1-59259-864-1:175
Trastuzumab Resistance in Breast Cancer
Morgillo, F., Orditura, M., Troiani, T., Martinelli, E., Vita, F. D., & Ciardiello, F. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0094-1_3
Autres traitements ciblés (trastuzumab exclu)
Fumoleau, P., Campone, M., Coudert, B. P., Mayer, F., Favier, L., & Ferrant, E. (2008) · Springer eBooks · doi:10.1007/978-2-287-71478-8_42
Epidermal growth factor receptor family activation and intracellular signaling: Implications for cancer therapeutics
Richman, J. M. (2008)

Authors: Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., Scher, H. I., & Sliwkowski, M. X.
Affiliations: Cedars-Sinai Medical Center (US)
Genentech (US)
Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Sliwkowski, Mark X
ORCID: Agus, David B
Scher, Howard I
Sliwkowski, Mark X
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2002-08
Volume: 2
Issue: 2
Pages: 127-137
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/s1535-6108(02)00097-1
OpenAlex: W2014457594
Cited by: 873
References: 83
Citations by year: 2026: 2 · 2025: 10 · 2024: 21 · 2023: 38 · 2022: 21 · 2021: 21 · 2020: 28 · 2019: 29 · 2018: 27 · 2017: 24 · 2016: 38 · 2015: 48 · 2014: 69 · 2013: 59 · 2012: 51
FWCI: 16.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 4003 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: PepsiCo
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: ERBB2, HER2, HER3, neuregulin-1, ErbB receptor family, breast cancer, prostate cancer, tumor growth inhibition, tyrosine kinase inhibitors
MeSH terms: Androgens, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Cell Division, Female, Humans, Ligands, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Binding, RNA, Messenger, Time Factors, Transplantation, Heterologous, Tumor Cells, Cultured, Signal Transduction, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Neuregulin-1, Receptor, ErbB-3, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks